Pinometostat

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103179

1380288-87-8

C103179

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116977

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157712

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C177537

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157711

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C63923

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C176424

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128784

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116978

CTRP

GDC

FDA

A small molecule inhibitor of histone methyltransferase with potential antineoplastic activity. Upon intravenous administration, pinometostat specifically blocks the activity of the histone lysine-methyltransferase DOT1L, thereby inhibiting the methylation of nucleosomal histone H3 on lysine 79 (H3K79) that is bound to the mixed lineage leukemia (MLL) fusion protein which targets genes and blocks the expression of leukemogenic genes. This eventually leads to an induction of apoptosis in the leukemic cells bearing the MLL gene translocations. DOT1L, a non-SET domain-containing histone methyltransferase, specifically methylates H3K79 and plays a key role in normal cell differentiation and in the development of leukemia with MLL gene rearrangement on chromosome 11 and promotes the expression of leukemia-causing genes.

Pinometostat

8V9YR09EF3

PINOMETOSTAT

DOT1L Inhibitor EPZ-5676

EPZ-5676

Pinometostat

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C73703

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1909

Pinometostat

Pinometostat

740411

740411

740411

Pinometostat

Thesaurus:C103179

Pinometostat

Pharmacologic Substance

C3641112

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C471